Huang J, Nalli AD, Mahavadi S, Kumar DP, Murthy KS. Inhibition of G␣ i activity by G␤␥ is mediated by PI 3-kinase-␥-and cSrc-dependent tyrosine phosphorylation of G␣i and recruitment of RGS12. Am J Physiol Gastrointest Liver Physiol 306: G802-G810, 2014. First published February 27, 2014 doi:10.1152/ajpgi.00440.2013.-Others and we have characterized several G␤␥-dependent effectors in smooth muscle, including G protein-coupled receptor kinase 2 (GRK2), PLC␤ 3, and phosphatidylinositol (PI) 3-kinase-␥, and have identified various signaling targets downstream of PI 3-kinase-␥, including cSrc, integrin-linked kinase, and Rac1-Cdc42/p21-activated kinase/p38 MAP kinase. This study identified a novel mechanism whereby G␤␥ acting via PI 3-kinase-␥ and cSrc exerts an inhibitory influence on G␣ i activity. The Gi2-coupled ␦-opioid receptor agonist D-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of G␣ i2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a G␤␥-scavenging peptide. Inhibition of forskolinstimulated cAMP and muscle relaxation by DPDPE was augmented by PP2, LY294002, and a selective PI 3-kinase-␥ inhibitor, AS-605420. Expression of tyrosine-deficient (Y69F, Y231F, or Y321F) G␣i2 mutant or knockdown of RGS12 blocked G␣i2 phosphorylation and G␣i2-RGS12 association and caused greater inhibition of cAMP. Parallel studies using somatostatin, cyclopentyl adenosine, or ACh to activate, respectively, Gi1-coupled somatostatin (sstr3) receptors, and Gi3-coupled adenosine A1 or muscarinic m2 receptors elicited cSrc activation, G␣i1 or G␣i3 phosphorylation, G␣i1-RGS12 or G␣i3-RGS12 association, and inhibition of cAMP. Inhibition of cAMP and muscle relaxation was greatly increased by AS-605240 and PP2. The results demonstrate that G␤␥-dependent tyrosine phosphorylation of G␣i1/2/3 by cSrc facilitated recruitment of RGS12, a G␣i-specific RGS protein with a unique phosphotyrosine-binding domain, resulting in rapid deactivation of G␣i and facilitation of smooth muscle relaxation.
RECEPTOR-MEDIATED G protein signaling requires the participation of the complete heterotrimer. In recent years, increasing attention has focused on the role of the G␤␥ complex in effector regulation (6, 10, 12, 32) . The G␤␥ complex is bound to the plasma membrane via isoprenylated G␥; it participates in G protein-receptor coupling and acts as a guanine nucleotide dissociation inhibitor, maintaining the G protein in its inactive state (10, 29) . Agonist-activated receptors catalyze the exchange of GDP for GTP; binding of GTP to G␣ induces a conformational change in three flexible switch regions within G␣ that result in dissociation of G␤␥ (7) . G␣-GTP and free G␤␥ subunits regulate distinct downstream effector molecules.
The intrinsic hydrolysis of GTP by G␣, greatly accelerated by regulator of G protein signaling (RGS) proteins (29, 36) , terminates the cycle of guanine nucleotide exchange and fosters reassociation of G␣-GDP with G␤␥.
G␤␥ undergoes little or no conformational change and, unlike G␣, has no catalytic activity, acting on its effectors via protein-protein interaction (32) . In the inactive state, G␤␥ interacts with two structural components of G␣: the G␣ NH 2 -terminal helix and the G␣ switch II region; the latter undergoes a conformational change upon GTP binding that leads to release of G␤␥ subunits, exposing a signaling surface on G␤ (7, 15) . Various subsets of amino acids within this preferred binding surface on G␤, together with complementary sites in other regions of G␤␥, are involved in binding and activation of different effectors.
Most G␤␥ signaling arises from abundant G i proteins and is susceptible to inhibition by pertussis toxin, which ADP-ribosylates G␣ i , preventing guanine nucleotide exchange on G␣ and dissociation of G␤␥ (6, 32) . Numerous G␤␥ effectors, including PLC␤ 2 and PLC␤ 3 , adenylyl cyclases (I-VII), N/P/ Q-type Ca 2ϩ channels, inwardly rectifying K ϩ channels, phosphoinositide (PI) 3-kinase-␥, and G protein-coupled receptor kinases (GRK2 and GRK3), have been identified in various cells (4, 12, 28, 32, 34) . Others (9, 17, 31, 35, 37) and we (8, 19, 20 -24, 39) have characterized the signaling pathways mediated by several of these G␤␥-dependent effectors, including GRK2, PLC␤3, and PI 3-kinase, in smooth muscle and have identified various signaling targets downstream of PI 3-kinase, including Rac1/cdc42, p21-activated kinase (PAK1), integrin-linked kinase (ILK), and cSrc (8, 19, 30, 39) . Previous studies using freshly dispersed or cultured gastric smooth muscle cells, a model system used extensively to explore G protein-coupled receptor signaling in visceral smooth muscle, have shown that receptors coupled to G i1 [e.g., somatostatin (sstr 3 )] (21), G i2 (e.g., -, ␦-, and -opioid) (23), or G i3 (e.g., adenosine A 1 ) (22) induce contraction by activating dual signaling pathways initiated by G␤␥ (8) : the first pathway involves activation of PLC␤ 3 , stimulation of inositol 1,4,5-trisphosphate-dependent Ca 2ϩ release, and phosphorylation of myosin light chain 20 (MLC 20 ) , resulting in a transient smooth muscle contraction. The second pathway involves sequential activation of PI 3-kinase and ILK: the latter acts as a Ca 2ϩ -independent MLC kinase and inhibits MLC phosphatase (PP1c␦), resulting in sustained MLC 20 phosphorylation and smooth muscle contraction (5, 8) . In the present study we examined the significance of a parallel pathway initiated by these receptors and by G i3 -coupled muscarinic m 2 receptors involving sequential activation of G␤␥, PI 3-kinase-␥, and cSrc. We postulated that G␣ i could be a target for tyrosine phosphorylation by cSrc, enabling tyrosine-phosphorylated G␣ i to recruit RGS12, a G␣ i -selective RGS protein, which uniquely contains an NH 2 -terminal phosphotyrosine-binding (PTB) domain (30) . In this way, a signal emanating from G␤␥ could accelerate inactivation of G␣ i -GTP and facilitate reassociation of G␣ and G␤␥ into an inactive heterotrimer.
MATERIALS AND METHODS

Materials.
125 I-cAMP was obtained from PerkinElmer Life Sciences (Boston, MA); collagenase CLS type II and soybean trypsin inhibitor from Worthington (Freehold, NJ); Western blotting Tris·HCl Ready Gel from Bio-Rad Laboratories (Hercules, CA); phosphotyrosine, phosphorylated (Tyr 416 ) Src, PI 3-kinase-␥, RGS12, G␣i1, G␣i2, and G␣i3 antibodies and RGS12 small interfering RNA (siRNA) from Santa Cruz Biotechnology (Santa Cruz, CA); LY294002, PP2, and AS-605240 from Calbiochem (La Jolla, CA); Lipofectamine 2000 transfection reagent from Invitrogen (Grand Island, NY); DMEM from Fisher Scientific; and D-penicillamine (2,5)-enkephalin (DPDPE), cyclopentyl adenosine (CPA), somatostatin, ACh, 1,1-dimethyl-4-diphenylacetoxypiperidinium iodide (4-DAMP), and all other chemicals from Sigma (St. Louis, MO).
New Zealand white rabbits (4 -5 lb body wt) were purchased from RSI Biotechnology (Clemmons, NC) and euthanized by injection of Euthasol (100 mg/kg), as approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth University. C57BL/6 mice (Jackson laboratories, Bar Harbor, ME) were housed in the animal facility administered by the Division of Animal Resources, Virginia Commonwealth University. All procedures were conducted in accordance with the Institutional Animal Care and Use Committee of Virginia Commonwealth University. Human tissues were obtained from the National Disease Research Interchange.
Preparation of dispersed and cultured gastric smooth muscle cells. Smooth muscle cells from the circular muscle layer of the distal stomach were isolated by sequential enzymatic digestion of muscle strips, filtration, and centrifugation, as described previously (8, 20 -22) . The tissue was cut into thin slices using a Stadie-Riggs tissue slicer, and the slices were incubated at 31°C for 30 min in a smooth muscle buffer [120 mM NaCl, 4 mM KCl, 2.6 mM KH 2PO4, 2.0 mM CaCl2, 0.6 mM MgCl2, 25 mM HEPES, 14 mM glucose, and 2.1% essential amino acid mixture (pH 7.4)] containing 0.1% collagenase (300 U/ml) and 0.01% (wt/vol) soybean trypsin inhibitor. The tissue was continuously gassed with 100% O 2 throughout the isolation procedure. The partly digested tissues were washed twice with 50 ml of collagenase-free smooth muscle buffer, and the muscle cells were allowed to disperse spontaneously for 30 min in collagenase-free medium. The cells were harvested by filtration through 500-m Nitex and centrifuged twice at 350 g for 10 min to eliminate broken cells and organelles. The cells were counted in a hemocytometer, and ϳ95% of the cells excluded Trypan blue. Experiments were done within 2-3 h of cell dispersion.
For culture, freshly dispersed smooth muscle cells were resuspended in DMEM containing penicillin (200 U/ml), streptomycin (200 g/ml), gentamicin (100 g/ml), amphotericin B (2.5 g/ml), and 10% FBS (DMEM-10). The cells were plated at 5 ϫ 10 5 cells/ml and incubated at 37°C in a CO2 incubator. DMEM-10 was replaced every 3 days for 2-3 wk until confluence was attained. The smooth muscle cells in confluent primary cultures were trypsinized (0.5 mg trypsin/ml), replated at 2.5 ϫ 10 5 cells/ml, and cultured under the same conditions. All experiments were done on cells in passage 1. The purity of cultured smooth muscle cells was previously determined using smooth muscle-specific ␥-actin (33) . Cultured smooth muscle cells were placed in serum-free medium for 24 h before each use.
Transfection of cultured smooth muscle cells with RGS12 siRNA. Smooth muscle cells cultured in six-well plates were transiently transfected with control scrambled siRNA or RGS12 siRNA using Lipofectamine 2000 according to the manufacturer's instructions (8) . Briefly, 100 pmol of siRNA in 125 l of Opti-MEM were mixed with 5 l of Lipofectamine 2000 in 125 l of Opti-MEM. The mixture was incubated at room temperature for 20 min and added to wells containing 1.5 ml of DMEM with 10% FBS for 1 day. The medium was then replaced with DMEM with 10% FBS ϩ antibiotics for 2 days. The cells were maintained for a final 24 h in DMEM without FBS before experiments were started. Successful knockdown of RGS12 protein was verified by Western blotting (8, 24, 39) .
Vector and G␣ i2 mutant constructs and transfection of smooth muscle cells with wild-type and mutant G␣ i2. Mutant phosphorylation site-deficient G␣ i2 (Y69, Y231, or Y321) was constructed by the megaprimer method, as described previously (40) . Mutants were sequenced to confirm that mutagenesis was successful. Wild-type G␣ i2 and phosphorylation site-deficient G␣i2 were subcloned separately into the multiple cloning site (EcoR I) of the eukaryotic expression vector pEXV. Recombinant plasmid DNAs (2 g each) were transiently transfected into smooth muscle cells in passage 1 by incubation with Lipofectamine Plus reagent for 48 h. The cells were cotransfected with 1 g of pGreen Lantern-1 to monitor expression. Control cells were cotransfected with 2 g of vector (pEXV) and 1 g of pGreen Lantern-1 DNA. Transfection efficiency (ϳ75%) was monitored by the expression of green fluorescent protein using FITC filters.
Activation of cSrc. Activation of cSrc was measured by immunoblotting using a phosphorylated (Tyr 416 ) Src antibody. Freshly dispersed smooth muscle cells (3 ϫ 10 6 cells/ml) were pretreated for 10 min with control buffer or buffer containing inhibitors of PI 3-kinase (LY294002, 1 M) or cSrc (PP2, 1 M) followed by addition of 1 M DPDPE for 1 min. The cell suspension was solubilized on ice for 2 h in 20 mM Tris·HCl medium containing 1 mM DTT, 100 mM NaCl, 0.5% SDS, 1 mM PMSF, 10 g/ml leupeptin, and 100 g/ml aprotinin. In other experiments, cultured smooth muscle cells in passage 1 were transfected with control vector or vector containing GRK2CT-(495-689), a G␤␥-scavenging peptide. The cells were treated with DPDPE for 1 min and then solubilized as described above. The proteins were resolved by SDS-PAGE and transferred electrophoretically to polyvinylidene difluoride (PVDF) membranes. The membranes were incubated for 12 h with phosphorylated (Tyr 416 ) Src antibody and then for 1 h with horseradish peroxidase-conjugated secondary antibody. The bands were identified by enhanced chemiluminescence.
Phosphorylation of G␣i. Dispersed smooth muscle cells (3 ϫ 10 6 cells/ml) were pretreated for 10 min with control buffer or buffer containing inhibitors of PI 3-kinase (LY294002, 1 M) or cSrc (PP2, 1 M) followed by addition of 1 M DPDPE. The cell suspension was solubilized on ice for 2 h in 20 mM Tris·HCl medium containing 1 mM DTT, 100 mM NaCl, 0.5% SDS, 1 mM PMSF, 10 g/ml leupeptin, and 100 g/ml aprotinin. In other experiments, smooth muscle cells cultured in wells were transfected separately with control vector, vector containing GRK2CT-(495-689), or vector containing G␣i2 mutant (Y69F, Y231F, or Y321F), treated with DPDPE for 1 min, and then solubilized as described above. G␣i2 immunoprecipitates were separated by SDS-PAGE, transferred to PVDF membranes, and probed with phosphorylated tyrosine antibody. After incubation with a secondary antibody, the proteins were visualized using enhanced chemiluminescence. In some experiments, dispersed smooth muscle cells (3 ϫ 10 6 cells/ml) were treated, respectively, with somatostatin (1 M) to activate G␣i1-coupled somatostatin sstr3 receptors, ACh (1 M) in the presence of the muscarinic m3 receptor antagonist 4-DAMP (0.1 M) to activate G␣i3-coupled m2 receptors, or CPA (1 M) to activate G␣i3-coupled adenosine A1 receptors. Phosphorylation of G␣i1 and G␣i3 was analyzed as described above for G␣i2.
Immunoblot analysis of G␣i-RGS12 association. Dispersed smooth muscle cells (3 ϫ 10 6 cells/ml) were pretreated for 10 min with control buffer or buffer containing inhibitors of PI 3-kinase (LY294002, 1 M) or cSrc (PP2, 1 M) followed by addition of 1 M DPDPE. In other experiments, smooth muscle cells cultured in wells were transfected with control vector, vector containing GRK2CT-(495-689), or vector containing G␣i2 mutant (Y69F, Y231F, or Y321F). The cells were treated with 1 M DPDPE for 1 min and solubilized as described above. G␣i2 immunoprecipitates were obtained from lysates of freshly dispersed or cultured muscle cells. The immunoprecipitates were separated by SDS-PAGE, transferred to PVDF membranes, and probed with RGS12 antibody. After incubation with secondary antibody, the proteins were visualized by enhanced chemiluminescence. The intensity of the protein bands was determined by densitometry.
In separate experiments, dispersed smooth muscle cells (3 ϫ 10 6 cells/ml) were treated for 1 min with 1 M somatostatin, 1 M CPA, or 1 M ACh ϩ 0.1 M 4-DAMP. G␣i1 immunoprecipitates were obtained from lysates of cells treated with somatostatin, and G␣i3 immunoprecipitates were obtained from lysates of cells treated with CPA or ACh. Immunoprecipitates were probed with RGS12 antibody as described above for analysis of G␣i-RGS12 association. Radioimmunoassay for cAMP. cAMP levels were measured by radioimmunoassay, as previously described (20 -23) . Suspensions of smooth muscle cells (2 ϫ 10 6 cells/ml) were incubated for 10 min with 100 M isobutylmethyl xanthine and 10 M forskolin and then treated for 1 min with 1 M DPDPE. In separate experiments, the cells were first treated for 10 min with 1 M LY294002 or 1 M PP2 and then for 1 min with 1 M DPDPE. In some experiments, the cells were treated with 1 M somatostatin, 1 M ACh ϩ 0.1 M 4-DAMP, or 1 M CPA for 1 min, with or without pretreatment with the PI 3-kinase-␥-selective inhibitor AS-605240 (25 nM) or PP2 (1 M). In other experiments, cultured smooth muscle cells were transfected with control vector, vector containing GRK2CT-(495-689), or vector containing G␣i2 mutant. The cells were then treated with forskolin and DPDPE as described above. The reaction was terminated with 10% trichloroacetic acid. The samples were centrifuged, and the supernatant was extracted with diethyl ether and lyophilized. The samples were resuspended in sodium-acetate buffer (pH 6.2) and then acetylated with triethylamine-acetic anhydride for 10 min. cAMP was measured in duplicates, and the results are expressed as picomoles per milligram of protein.
Measurement of relaxation in dispersed smooth muscle cells. Contraction in freshly dispersed smooth muscle cells was determined by scanning micrometry (21) (22) (23) (24) ). An aliquot (0.4 ml) of cells containing ϳ10 4 cells/ml was treated with KCl (20 mM) for 30 s, and the reaction was terminated with 1% acrolein at a final concentration of 0.1%. The mean lengths of 50 muscle cells treated with KCl were measured by scanning micrometry and compared with the mean lengths of untreated cells. The contractile response to KCl is expressed as the percent decrease in mean cell length from control cell length. Relaxation was measured as decrease in response to KCl in the presence of 10 M forskolin. Relaxation is expressed as percent decrease in contractile response to KCl.
Statistical analysis. Values are means Ϯ SE of n experiments, where n represents one sample from one animal for a single experimental replicate. Results were analyzed for statistical significance using Student's t-test for paired and unpaired values. P Ͻ 0.05 was considered to be statistically significant. The GraphPad software program (San Diego, CA) was used for statistical analysis.
RESULTS
DPDPE-stimulated phosphorylation of cSrc mediated by G␤␥-dependent activation of PI 3-kinase.
Treatment of cultured smooth muscle cells with the ␦-opioid receptor agonist DPDPE stimulated cSrc phosphorylation, determined using phosphorylated (Tyr 416 ) Src antibody; phosphorylation was abolished in cells expressing the COOH-terminal sequence of GRK2 that constitutes the G␤␥ binding motif (Fig. 1A) . The COOH-terminal sequence of GRK2 acts as a specific G␤␥ (but not G␣) antagonist by binding to G␤␥ and blocking its interaction with effectors such as GRK2 (14, 16, 18, 38) . Treatment of freshly dispersed smooth muscle cells with DPDPE also stimulated cSrc phosphorylation, which was abolished in smooth muscle cells pretreated with the cSrc inhibitor PP2 or the PI 3-kinase inhibitor LY294002 (Fig. 1B) . The results from freshly dispersed and cultured smooth muscle cells implied that cSrc phosphorylation was mediated by G␤␥-dependent activation of PI 3-kinase.
DPDPE-stimulated tyrosine phosphorylation of G␣ i2 mediated by G␤␥-dependent activation of PI 3-kinase and cSrc. We considered whether G␣ i2 was a possible target for tyrosine phosphorylation by cSrc. The sequence of G␣ i2 contains several sites for tyrosine phosphorylation by cSrc. Treatment of cultured smooth muscle cells with DPDPE stimulated tyrosine phosphorylation of G␣ i2 , which was abolished in smooth muscle cells expressing G␤␥-scavenging peptide [GRK2CT-(495-689)] (Fig. 1A) . Treatment of freshly dispersed smooth muscles with DPDPE also stimulated tyrosine phosphorylation of G␣ i2 , which was abolished in cells pretreated with LY294002 or PP2 (Fig. 1B) . The results implied that tyrosine phosphorylation of G␣ i2 was mediated by G␤␥-dependent sequential activation of PI 3-kinase and cSrc.
Recruitment of RGS12 by tyrosine-phosphorylated G␣ i2 . We next examined whether tyrosine phosphorylation enabled G␣ i2 to recruit RGS12. This multidomain RGS12 has high affinity for G␣ i and contains a unique PTB domain (29, 30) . Treatment of cultured smooth muscle cells with DPDPE induced RGS12-G␣ i2 association, which was abolished in cells expressing G␤␥-scavenging peptide [GRK2CT-(495-689)] (Fig. 1A) . Treatment of freshly dispersed smooth muscle cells with DPDPE also induced RGS12-G␣ i2 association, which was abolished in cells pretreated with LY294002 or PP2 (Fig.  1B) . The results implied that tyrosine phosphorylation of G␣ i2 mediated by G␤␥-dependent activation of PI 3-kinase and cSrc enabled recruitment of RGS12.
G␣ i2 -mediated inhibition of cAMP and muscle relaxation is attenuated by G␤␥-dependent activation of PI 3-kinase-␥ and cSrc. To define the functional significance of this pathway, we determined its ability to influence inhibition of cAMP formation by DPDPE. DPDPE inhibited forskolin-stimulated cAMP
Treatment of cultured smooth muscle cells with DPDPE inhibited forskolin-stimulated cAMP formation by 45 Ϯ 4% (n ϭ 5); the inhibition was greatly enhanced (90 Ϯ 3%, n ϭ 5) in cells expressing G␤␥-scavenging peptide [GRK2CT-(495-689)] (P Ͻ 0.01; Fig. 2A ). Treatment of freshly dispersed smooth muscle cells with DPDPE also inhibited forskolinstimulated cAMP formation by 43 Ϯ 2% (n ϭ 5); the inhibition was greatly enhanced in cells pretreated with LY294002 (88 Ϯ 4%, n ϭ 5), AS-605240, a PI 3-kinase ␥-selective inhibitor (86 Ϯ 5%, n ϭ 5), or PP2 (92 Ϯ 5%, n ϭ 5) (Fig. 2B) . The results implied that inhibition of adenylyl cyclase activity by G␣ i2 was strongly influenced (i.e., attenuated) by G␤␥-dependent activation of PI 3-kinase and cSrc. Forskolin-induced cAMP formation was not affected in the presence of LY294002 or PP2, suggesting that adenylyl cyclase activity was not affected by PI 3-kinase or cSrc.
Expression of PI 3-kinase-␥ was demonstrated by Western blotting in rabbit, mouse, and human gastric muscle cells (Fig. 3A) . Treatment of freshly dispersed smooth muscle cells from rabbit stomach with DPDPE also inhibited forskolin-stimulated muscle relaxation by 39 Ϯ 4% (n ϭ 5); the inhibition was greatly enhanced in cells pretreated with LY294002 (75 Ϯ 3%, n ϭ 5), AS-605240, a PI 3-kinase-␥-selective inhibitor (81 Ϯ 5%, n ϭ 5), or PP2 (73 Ϯ 3%, n ϭ 5) (Fig. 3B) . Similarly, treatment of freshly dispersed smooth muscle cells from mouse and human stomach with DPDPE also inhibited forskolin-stimulated muscle relaxation by 41 Ϯ 3% and 37 Ϯ 2% (n ϭ 5); the inhibition was greatly enhanced in cells pretreated with AS-605240 (75 Ϯ 4% and 73 Ϯ 5%, n ϭ 5; Fig. 3, C and D) . The results implied that inhibition of muscle relaxation by the G␣ i2 -coupled ␦-opioid receptor agonist DPDPE was attenuated by activation of PI 3-kinase-␥ and cSrc.
Role of RGS12 in G␤␥-dependent modulation of G␣ i2 function. The role of tyrosine phosphorylation of G␣ i2 in recruitment and activity of RGS12 was examined further by mutation of three putative tyrosine phosphorylation sites (Y69F, Y231F, and Y321F) in G␣ i2 to phenylalanine. Expression of tyrosine-deficient G␣ i2 mutant in cultured smooth muscle cells had no effect on cSrc activation but blocked DPDPE-induced tyrosine phosphorylation of G␣ i2 and G␣ i2 -RGS12 association (Fig. 4A) and caused greater inhibition of forskolin-stimulated cAMP (control inhibition: 46 Ϯ 3% vs. 91 Ϯ 4% in cells expressing mutant G␣ i2 , P Ͻ 0.01, n ϭ 5; Fig. 4B ), providing evidence that tyrosine phosphorylation of G␣ i2 increases G␣ i2 -RGS12 association and accelerates G␣ i2 inactivation.
Further evidence was obtained in smooth muscle cells expressing RGS12 siRNA. In these cells, cSrc activation and G␣ i2 phosphorylation were not affected upon treatment with DPDPE, whereas G␣ i2 -RGS12 association was abolished (Fig.  4A) and inhibition of forskolin-stimulated cAMP was greatly enhanced (control inhibition: 47 Ϯ 5% vs. 92 Ϯ 3% after RGS12 knockdown, P Ͻ 0.01, n ϭ 5; Fig. 4B ), further confirming the role of RGS12 in inactivation of G␣ i2 .
Role of RGS12 in G␤␥-dependent modulation of G␣ i1 and G␣ i3 function. The close homology between G␣ i1 , G␣ i2 , and G␣ i3 and the presence of tyrosine phosphorylation sites in similar locations in all three subunits suggested that a similar G␤␥-G␣ i feedback mechanism was more widely applicable. Accordingly, we compared the effects of DPDPE with the effects of somatostatin, CPA, and ACh to examine whether the feedback regulatory mechanism applies to all G i subunits. In the gastrointestinal system, somatostatin, ␦-opioid, and CPA activate receptors coupled to G i1 , G i2 , and G i3 , respectively (21) (22) (23) . ACh in the presence of the m 3 receptor antagonist 4-DAMP activates m 2 receptors coupled to G i3 (24) . Somatostatin induced cSrc activation, tyrosine phosphorylation of G␣ i1 , and G␣ i1 -RGS12 association, and CPA and ACh induced cSrc activation, tyrosine phosphorylation of G␣ i3 , and G␣ i3 -RGS12 association (Fig. 5A) . Thus, G␤␥ dimers derived from all three G i proteins are capable of activating PI 3-kinase-␥ and cSrc to induce tyrosine phosphorylation of the corresponding G␣ i , recruitment of RGS12, and inhibition of G␣ i activity.
Treatment of freshly dispersed smooth muscle cells with somatostatin, CPA, or ACh inhibited forskolin-stimulated cAMP formation to the same extent as DPDPE (Fig. 5B) . The inhibition of cAMP was greatly enhanced in cells pretreated with the PI 3-kinase-␥-specific inhibitor AS-605240 (20 nM) (control inhibition of 46 Ϯ 3% to 54 Ϯ 5% with different agonists vs. 86 Ϯ 5% to 93 Ϯ 3% inhibition in the presence of AS-605240, P Ͻ 0.01, n ϭ 4) or PP2 (control inhibition of 48 Ϯ 4% to 57 Ϯ 4% with different agonists vs. 83 Ϯ 5% to 90 Ϯ 3% inhibition in presence of PP2, P Ͻ 0.01, n ϭ 4; Fig. 5B) .
Treatment of freshly dispersed smooth muscle cells with somatostatin, CPA, or ACh inhibited forskolin-stimulated relaxation to the same extent as DPDPE (Fig. 6 ). The inhibition of relaxation was greatly enhanced in cells pretreated with the PI 3-kinase-␥-specific inhibitor AS-605240 (20 nM) [control inhibition of 39 Ϯ 4% to 44 Ϯ 3% with different agonists vs. 71 Ϯ 4% to 77 Ϯ 5% inhibition in the presence of AS-605240 (P Ͻ 0.01, n ϭ 4) or 70 Ϯ 6% to 80 Ϯ 5% inhibition in the presence of PP2 (P Ͻ 0.01, n ϭ 4); Fig. 6 ].
DISCUSSION
The role of G␤␥ heterodimers in G protein-receptor coupling and guanine nucleotide exchange is now well established, as is their role in termination of the cycle and reassociation of the subunits into inactive G␣␤␥ heterotrimers. The present study in smooth muscle identifies a distinct role for G␤␥ in inactivation of G␣ i signaling. The extent and duration of G␣ i activity were shown to depend on signals emanating from G␤␥ to downstream effectors. G␤␥ sequentially activated PI 3-kinase-␥ and cSrc, leading to tyrosine phosphorylation of G␣ i , recruitment of RGS12, and rapid inactivation of G␣ i (Fig. 7) . Detailed evidence obtained for G␣ i2 -coupled ␦-opioid receptors can be summarized as follows. 1) DPDPE activated cSrc, stimulated tyrosine phosphorylation of G␣ i2 , and induced G␣ i2 -RGS12 association; all three events were blocked by PI 3-kinase and cSrc inhibitors and by expression of a G␤␥-scavenging peptide (COOH-terminal sequence of GRK2).
2) Inhibition of forskolin-stimulated cAMP formation by DP-DPE was augmented by PI 3-kinase-␥ and cSrc inhibitors and by expression of G␤␥-scavenging peptide. 3) Inhibition of forskolin-stimulated muscle relaxation by DPDPE was augmented by PI 3-kinase-␥ and cSrc inhibitors. 4) Expression of tyrosine-deficient G␣ i2 mutant or knockdown of RGS12 blocked G␣ i2 phosphorylation and G␣ i2 -RGS12 association and caused greater inhibition of cAMP formation. 5) Inhibition of cAMP formation and muscle relaxation by DPDPE was also augmented in mouse and human gastric muscle cells. 6) Expression of PI 3-kinase-␥ was demonstrated in rabbit, mouse, and human gastric muscle cells.
Corroborating evidence was obtained for G␣ i1 -coupled somatostatin sstr 3 receptors and G␣ i3 -coupled adenosine A 1 and muscarinic m 2 receptors (21, 22) . This was not unexpected in view of the close homology between G␣ i1 , G␣ i2 , and G␣ i3 and the presence of tyrosine phosphorylation sites in locations similar to those mutated in G␣ i2 . The corresponding agonists, somatostatin, CPA, and ACh (the latter in the presence of the selective m 3 receptor antagonist 4-DAMP), induced G␣ i1 -RGS12 or G␣ i3 -RGS12 association and inhibited forskolininduced cAMP formation and muscle relaxation; inhibition of cAMP formation and muscle relaxation was increased by the PI 3-kinase-␥-selective inhibitor AS-605240 and by PP2. The effectiveness of AS-605240 underscored the fact that PI 3-kinase-␥, which consists of p110␥ catalytic and p101 noncatalytic regulatory subunits, is the singular class 1B member of the PI 3-kinase family activated by G␤␥ (2). PI 3-kinase-␥ is predominantly expressed in cells of the hematopoietic system, but it is also found in other tissues (1, 3) , including gastrointestinal, airway, and vascular smooth muscle (8, 21, 31, 33) . PI 3-kinase has been identified as an important regulator of vascular myogenic tone and blood pressure (3, 14) .
Previous studies in smooth muscle showed that G␤␥ subunits derived from G i1 , G i2 , or G i3 activate PLC␤ 3 and PI 3-kinase (8, 20 -23) . PLC␤ 3 initiates a signaling cascade that leads to transient activation of a Ca 2ϩ -dependent MLC kinase and stimulation of MLC 20 phosphorylation and smooth muscle contraction (21) (22) (23) . PI 3-kinase initiates a distinct signaling cascade that leads to Ca 2ϩ -independent, ILK-mediated inhibition of MLC phosphatase and sustained stimulation of MLC 20 phosphorylation and smooth muscle contraction (5, 8) . When initiated by muscarinic m 2 receptors, however, the same cascades are abrogated by a parallel cascade mediated by PI 3-kinase involving sequential activation of Rac1/cdc42, PAK1, and p38 MAP kinase (39) . As shown previously (24) , PAK1 inactivates Ca 2ϩ -dependent MLC kinase, whereas p38 MAP inactivates ILK (8) ; as a result, m 2 receptors are uncoupled from MLC 20 phosphorylation and smooth muscle contraction. The present study confirms the existence of a parallel pathway involving sequential activation of PI 3-kinase-␥ and cSrc that leads to inactivation of G␣ i .
From a physiological point of view, muscle relaxation in the gastrointestinal tract can be regulated by various endogenous agonists, such as vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide and peptide histidine isoleucine (19) . These agonist-specific receptors coupled to G s , activation of adenylyl cyclase, and cAMP formation (19) . Concomitant activation of receptors coupled to G␣ i by endogenous agonists such as adenosine, opioid peptides, and somatostatin inhibit cAMP formation. Rapid termination of G␣ i signaling by the feedback mechanism contributes to enhance the function of cAMP by minimizing the inhibition of cAMP formation and muscle relaxation. Occurrence of this feedback inhibitory pathway with receptors coupled to G␣ i1 , G␣ i2 , or G␣ i3 and in different species underscores the importance of this mechanism in the regulation of muscle function by neurotransmitters in the gastrointestinal tract.
The significance of the mechanism identified in this study depends on the convergence and interaction of four signaling proteins: G␤␥ derived from G i , PI 3-kinase-␥, cSrc, and RGS12. The multidomain RGS12 contains a NH 2 -terminal PDZ domain, dual Ras-binding domains, a COOH-terminal GoLoco motif, and a unique PTB domain; together, these Fig. 4 . Expression of tyrosine-deficient G␣i2 mutant or RGS12 small interfering RNA (siRNA) blocks G␣i2-RGS12 association and enhances DPDPE-induced inhibition of cAMP. A: cultured smooth muscle cells transfected with control vector, vector containing G␣i2 mutant (Y69F, Y231F, or Y321F), or RGS12 siRNA were treated with 1 M DPDPE for 1 min. Activation of cSrc (pSrc) was measured using specific phosphorylated (Tyr 416 ) Src antibody. G␣i2 immunoprecipitates were used to measure tyrosine phosphorylation (pG␣i2) using phosphotyrosine antibody and association of G␣i2 with RGS12 (RGS12-G␣i2) using RGS12 antibody. Immunoblots are representative of 4 separate experiments. b, Basal; d, DPDPE. Expression of G␣i2 mutant had no effect on cSrc activation, whereas suppression of RGS12 had no effect on cSrc activation and G␣i2 phosphorylation. B: cultured smooth muscle cells transfected with control vector, vector containing G␣i2 mutant (Y69F, Y231F, or Y321F), or RGS12 siRNA were pretreated with 10 M forskolin for 10 min and then treated with 1 M DPDPE for 1 min. cAMP levels were measured by radioimmunoassay. Basal levels (2. domains endow RGS12 with the ability to interact with a variety of proteins (30) . The RGS domain and the GoLoco motif display high affinity for G␣ i -GTP and G␣ i -GDP, respectively, while the PTB domain interacts with many, but not all, target proteins, with a canonical Asn-Pro-X-(p)Tyr binding motif (13, 27) . RGS12 association with G␣ i1 , G␣ i2 , and G␣ i3 was evident in our study, even though none of the putative tyrosine phosphorylation sites in G i displayed a canonical PTB motif.
Unlike G i , cSrc, and RGS12, which are widely expressed, PI 3-kinase-␥, as noted above, appears to exhibit a more limited tissue distribution, which would limit a wider applicability of the mechanism described in this study. Furthermore, consideration should be given to the issue of differential sensitivity of PI 3-kinase-␥ to isoforms of G␤␥. G␤ 1-4 exhibit close homology, sharing 78 -88% amino acid identity, and are widely expressed or coexpressed in various tissues, whereas G␥ 1-13 subunits are more diverse in sequence and tissue expression (6, 12, 26) . Some G␥ subunits are restricted to the retina (G␥ 7,9 ), others are preferentially expressed in the brain (G␥ 2,3,4,7 ) and olfactory and taste receptor cells (G␥ 8, 13 ), while others (G␥ 5, 10, 11, 12 ) are more widely expressed in various tissues (28) . In in vitro systems, all four G␤ subunits bound to 9 of 12 G␥ subunits and activate PI 3-kinase-␥ with varying potencies (11). Kerchner and co-workers (11) used pure recombinant G protein subunits to examine the ability of various G␤␥ combinations to activate PI 3-kinase-␥. When bound to G␥ 2 , all G␤ subunits, except G␤ 5 , were equally potent activators of PI 3-kinase-␥. The effectiveness of G␥ isoforms was traced to the isoprenyl group associated with this subunit. G␥ subunits modified by a geranylgeranyl group at their COOH terminus were highly effective, whereas G␥ 1, 8, 11 , which are modified by a farnesyl group, were not. Substitution of one prenyl group for the other reversed the ability of G␤␥ to activate PI 3-kinase-␥. These findings suggest that the composition of the G␤␥ complex and its affinity for PI 3-kinase-␥ may be of critical importance for the operation of the feedback mechanism involving G␤␥-mediated regulation of G␣ i activity.
In summary, we have identified a novel feedback mechanism for the termination of G␣ i signaling in smooth muscle cells. We have provided compelling evidence that G␤␥-dependent activation of the PI 3-kinase-␥-cSrc pathway and tyrosine phosphorylation of G␣ i leads to recruitment of GTPase-activating protein RGS12 and inactivation of G␣ i . This regulating mechanism attenuates the inhibition of cAMP formation and facilitates muscle relaxation.
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